Neurorehabilitation News

Higher education levels may protect against cognitive and functional difficulties for Black individuals with high levels of tau, indicating Alzheimer’s pathology, according to research from the Journal of Alzheimer’s Disease.

A Cincinnati-based life sciences company announced that one of its development candidates, ASHA-624, will be advanced as a potential disease modifying therapy for amyotrophic lateral sclerosis.

Despite the brain being one of the most important organs of the body, breakthroughs in brain health, specifically the way we measure cognition, have been largely unchanged in decades.

A United Kingdom-based clinical-stage biotech company has announced commencement of a first-in-human clinical trial of a selective central nervous system-penetrant compound to treat Parkinson’s disease.

The FDA has granted clearance to a transcranial magnetic stimulation device as an adjunctive treatment for major depressive disorder in patients aged 15 to 21 years, according to the manufacturer.

March is Multiple Sclerosis Awareness Month, a time to improve knowledge of and highlight the growing treatment options for progressive types of this degenerative disease.

IGC Pharma has announced positive interim results from an ongoing phase 2 trial investigating IGC-AD1, a natural THC-based oral formulation, as a treatment for agitation in dementia from Alzheimer’s disease.

A Boston-area developer of brain-computer interface technology and a Canadian biotech firm have announced a collaboration to globally commercialize the former’s brain health tools.

Two separate studies found no evidence to link anomalous health incidents with MRI-based biomarkers of disease or adverse results of neuropsychological testing among U.S. government staff, their families and matched controls.

Bristol Myers Squibb has completed its acquisition of Karuna Therapeutics, including Karuna’s therapeutic portfolio featuring a novel, investigational muscarinic antipsychotic to treat schizophrenia and Alzheimer’s disease.